Your session is about to expire
← Back to Search
CT1812 for Alzheimer's Disease
Study Summary
This trial is testing a new drug for Alzheimer's Disease. The study will last 36 weeks and will compare the new drug to a placebo.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain scan shows significant issues like large strokes or tumors.My recent MRI supports my Alzheimer's diagnosis without major issues.I will use condoms or my partner will use birth control during and 3 months after the trial.I am 50-85 years old with mild to moderate Alzheimer's and a documented decline in cognitive function over the last 6 months.I am a woman who cannot become pregnant because I am postmenopausal, had my tubes tied, or had a hysterectomy.Your score on the Mini-Mental State Examination (MMSE) is between 18 and 26.I have been diagnosed with major depression, schizophrenia, or bipolar disorder but am stable on medication.My condition is stable and won't affect the trial's outcome.I have been diagnosed with a type of dementia other than Alzheimer's.My Alzheimer's diagnosis was confirmed by a special brain scan or a spinal fluid test.You have symptoms or test results showing other diseases that affect the brain and nervous system, like syphilis, hypothyroidism, or vitamin deficiencies.I have symptoms or test results that suggest a condition like Parkinson's or ALS.I have been diagnosed with a seizure disorder.
- Group 1: Placebo Comparator - Placebo
- Group 2: Active Treatment- CT1812 100 mg
- Group 3: Active Treatment- CT1812 300 mg
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are currently involved in this medical research project?
"Affirmative. Clinicaltrials.gov provides evidence that this trial, which was posted on October 2nd 2018 and recently revised November 9th 2022, is actively searching for 144 patients from 12 different sites."
Does this trial accept participants aged 25 and over?
"The study is only accepting candidates aged between 50 and 85 years."
Can individuals still sign up for participation in this experiment?
"According to the clinicaltrials.gov portal, this research endeavour has been recruiting participants since October 2nd 2018 and was recently updated on November 9th 2022."
In how many distinct centers is this research managed?
"This trial is recruiting participants at 21st Century Neurology/ Xenoscience Inc. in Phoenix, Arizona, ActivMed Practices & Research, LLC in Methuen, Massachusetts and Ki Health Partners in Costa Mesa, California as well as a dozen additional medical centres."
Does Active Treatment- CT1812 300 mg pose any serious risks to the patient?
"Based on our evaluation, Active Treatment- CT1812 300 mg is rated a 2 due to limited clinical data regarding safety and efficacy."
Is it possible to become part of this research endeavor?
"This trial is recruiting 144 patients aged between 50 and 85 who are diagnosed with Alzheimer's disease. To qualify for the study, applicants must be male or non-childbearing female of a qualifying age range according to 2011 NIA-AA criteria as well as have experienced six months worth of cognitive decline that can be documented in patient records. Diagnostic confirmation through amyloid PET scan using florbetaben or another approved ligand will also be required, though previous positive results may suffice in lieu of conducting this test during screening. Alternately, diagnostic confirmation via CSF sample collected at the same visit will acceptably substitute an amyl"
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger